India: Pharma M&A deals dip to 5-year low in 2017 amid tough business conditions

India: Pharma M&A deals dip to 5-year low in 2017 amid tough business conditions

Photographer: Krisztian Bocsi/Bloomberg

Pharmaceutical companies have become cautious with regard to mergers and acquisitions (M&As) as business environment remains challenging due to pricing pressure and regulatory interventions in key markets—the US and India. This has led to a decline in volume as well as value of M&A deals in the pharma sector in the current year.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter